A fifteen year retrospective analysis showed that the survival of metastatic colorectal cancer (mCRC) patients treated with the first-line GOLFIG regimen was significantly longer than those treated with the FOLFOX regimen without GM-CSF (27). The gene discussed is CSF2; the disease is metastatic colorectal cancer.